Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial

Karina A. Keogh, Steven R Ytterberg, Fernando Custodio Fervenza, Kimberly A. Carlson, Darrell R. Schroeder, Ulrich Specks

Research output: Contribution to journalArticle

345 Citations (Scopus)

Abstract

Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data. Objectives: To evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis. Methods: A prospective open-label pilot trial was conducted with 10 patients monitored for 1 yr. Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/d) and four weekly infusions of rituximab (375 mg/m2). Prednisone was tapered and discontinued over 5 mo. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, and inability to complete the glucocorticoid taper were considered treatment failures. Main Results: Three women and seven men (median age, 57 yr; range, 25-72 yr) were enrolled. All had ANCA reacting with proteinase-3. The median activity score at enrollment was 6 (range, 5-10). All patients tolerated rituximab well, achieved swift B-lymphocyte depletion and complete clinical remission (activity score, 0) by 3 mo, and were tapered off glucocorticoids by 6 mo. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution. Conclusion: In this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume173
Issue number2
DOIs
StatePublished - Jan 15 2006

Fingerprint

Granulomatosis with Polyangiitis
Antineutrophil Cytoplasmic Antibodies
Remission Induction
B-Lymphocytes
Prednisone
Glucocorticoids
Myeloblastin
Lymphocyte Depletion
Salvage Therapy
Immunosuppressive Agents
Vasculitis
Treatment Failure
Cyclophosphamide
Biomarkers
Rituximab
Safety

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Rituximab for refractory Wegener's granulomatosis : Report of a prospective, open-label pilot trial. / Keogh, Karina A.; Ytterberg, Steven R; Fervenza, Fernando Custodio; Carlson, Kimberly A.; Schroeder, Darrell R.; Specks, Ulrich.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 173, No. 2, 15.01.2006, p. 180-187.

Research output: Contribution to journalArticle

@article{85ed3bb25daa48d4bb296a88f0557808,
title = "Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial",
abstract = "Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data. Objectives: To evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis. Methods: A prospective open-label pilot trial was conducted with 10 patients monitored for 1 yr. Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/d) and four weekly infusions of rituximab (375 mg/m2). Prednisone was tapered and discontinued over 5 mo. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, and inability to complete the glucocorticoid taper were considered treatment failures. Main Results: Three women and seven men (median age, 57 yr; range, 25-72 yr) were enrolled. All had ANCA reacting with proteinase-3. The median activity score at enrollment was 6 (range, 5-10). All patients tolerated rituximab well, achieved swift B-lymphocyte depletion and complete clinical remission (activity score, 0) by 3 mo, and were tapered off glucocorticoids by 6 mo. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution. Conclusion: In this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.",
author = "Keogh, {Karina A.} and Ytterberg, {Steven R} and Fervenza, {Fernando Custodio} and Carlson, {Kimberly A.} and Schroeder, {Darrell R.} and Ulrich Specks",
year = "2006",
month = "1",
day = "15",
doi = "10.1164/rccm.200507-1144OC",
language = "English (US)",
volume = "173",
pages = "180--187",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Rituximab for refractory Wegener's granulomatosis

T2 - Report of a prospective, open-label pilot trial

AU - Keogh, Karina A.

AU - Ytterberg, Steven R

AU - Fervenza, Fernando Custodio

AU - Carlson, Kimberly A.

AU - Schroeder, Darrell R.

AU - Specks, Ulrich

PY - 2006/1/15

Y1 - 2006/1/15

N2 - Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data. Objectives: To evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis. Methods: A prospective open-label pilot trial was conducted with 10 patients monitored for 1 yr. Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/d) and four weekly infusions of rituximab (375 mg/m2). Prednisone was tapered and discontinued over 5 mo. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, and inability to complete the glucocorticoid taper were considered treatment failures. Main Results: Three women and seven men (median age, 57 yr; range, 25-72 yr) were enrolled. All had ANCA reacting with proteinase-3. The median activity score at enrollment was 6 (range, 5-10). All patients tolerated rituximab well, achieved swift B-lymphocyte depletion and complete clinical remission (activity score, 0) by 3 mo, and were tapered off glucocorticoids by 6 mo. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution. Conclusion: In this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.

AB - Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data. Objectives: To evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis. Methods: A prospective open-label pilot trial was conducted with 10 patients monitored for 1 yr. Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/d) and four weekly infusions of rituximab (375 mg/m2). Prednisone was tapered and discontinued over 5 mo. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, and inability to complete the glucocorticoid taper were considered treatment failures. Main Results: Three women and seven men (median age, 57 yr; range, 25-72 yr) were enrolled. All had ANCA reacting with proteinase-3. The median activity score at enrollment was 6 (range, 5-10). All patients tolerated rituximab well, achieved swift B-lymphocyte depletion and complete clinical remission (activity score, 0) by 3 mo, and were tapered off glucocorticoids by 6 mo. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution. Conclusion: In this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.

UR - http://www.scopus.com/inward/record.url?scp=31944440872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944440872&partnerID=8YFLogxK

U2 - 10.1164/rccm.200507-1144OC

DO - 10.1164/rccm.200507-1144OC

M3 - Article

C2 - 16224107

AN - SCOPUS:31944440872

VL - 173

SP - 180

EP - 187

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -